Longevity peptides span an unusually wide evidence range, from FDA-approved drugs with extensive clinical data to Russian bioregulator peptides with decades of use but limited Western trial replication, to frontier compounds with only mechanistic evidence. This is a category where honest evidence rating matters most. This reference profiles 32 peptides and compounds studied for longevity, cellular repair, and healthy aging. Each is ranked by scientific evidence strength, with FDA status and international approval context clearly marked. From the Russian bioregulators (Epithalon, Thymalin, Vilon) to mitochondrial peptides (Humanin, MOTS-c, SS-31) to the GH-axis family, every compound is here, rated honestly.
Important: Star ratings measure evidence strength, not safety.
Every compound in this category, ranked by evidence strength.
| Peptide | FDA Status | Evidence | Key Note |
|---|---|---|---|
| Tesamorelin (Egrifta) | FDA-Approved | ★★★★★ | Approval is indication-specific |
| Insulin | FDA-Approved | ★★★★★ | Off-label use has very different evidence base |
| GHK-Cu | Cosmetic / Research | ★★★★☆ | Split rating |
| Thymosin Alpha-1 (Zadaxin) | Approved in 35+ countries / Research in US | ★★★☆☆ | Approved internationally; meaningful clinical immune data |
| Sermorelin | Formerly FDA-Approved / Compounded | ★★★☆☆ | Historical clinical use; longevity application preliminary |
| Epithalon (Epitalon) | Research | ★★★☆☆ | Russian/Eastern European human studies (Khavinson); limited Western RCT data |
| Thymalin | Research | ★★★☆☆ | Russian clinical studies; some human longevity data |
| Semax | Approved in Russia / Research in US | ★★★☆☆ | Human studies published; primarily Russian literature |
| Selank | Approved in Russia / Research in US | ★★★☆☆ | Human studies published; primarily Russian literature |
| SS-31 (Elamipretide) | Clinical-Stage Research | ★★★☆☆ | Phase II human trials; mitochondrial disease focus |
| GHRH (1-29) | Research | ★★★☆☆ | Equivalent to Sermorelin; similar evidence base |
| ARA-290 (Cibinetide) | Clinical-Stage Research | ★★★☆☆ | Phase II completed |
| Hexarelin | Research | ★★★☆☆ | Several human studies on GH axis |
| Ipamorelin | Research | ★★☆☆☆ | Some human GH data; longevity evidence preclinical |
| CJC-1295 DAC | Research | ★★☆☆☆ | Limited human efficacy data |
| IGF-1 LR3 | Research | ★★☆☆☆ | Primarily preclinical |
| IGF-1 DES | Research | ★★☆☆☆ | Primarily preclinical |
| IGF-2 | Research | ★★☆☆☆ | Primarily preclinical |
| Mechano Growth Factor (MGF) | Research | ★★☆☆☆ | Primarily animal |
| Pegylated MGF (PEG-MGF) | Research | ★★☆☆☆ | Primarily preclinical |
| Humanin | Research | ★★☆☆☆ | Mostly preclinical; early human observational data |
| MOTS-C | Research | ★★☆☆☆ | Mostly animal; early human studies |
| LL-37 | Research | ★★☆☆☆ | Some human antimicrobial data; longevity claims preclinical |
| N-Acetyl Semax | Research | ★★☆☆☆ | Less studied than Semax; limited human data |
| N-Acetyl Selank | Research | ★★☆☆☆ | Limited human data |
| N-Acetyl Semax Amidate | Research | ★★☆☆☆ | Very limited human data |
| N-Acetyl Selank Amidate | Research | ★★☆☆☆ | Very limited human data |
| Klotho Peptide Fragments | Research | ★★☆☆☆ | Primarily preclinical |
| Pinealon | Research | ★★☆☆☆ | Primarily Russian preclinical literature |
| Cortagen | Research | ★★☆☆☆ | Russian preclinical/limited human data |
| Vilon | Research | ★★☆☆☆ | Russian literature; limited independent replication |
| Dihexa | Research | ★☆☆☆☆ | Primarily animal; very early stage |
4 stars for topical/cosmetic use (strong evidence for skin repair and collagen stimulation), 2 stars for systemic use. One of the most versatile peptides in the longevity space, but the evidence depends heavily on how it's used.
The most-discussed longevity peptide. Russian/Eastern European human studies (Khavinson research) suggest telomerase activation and mortality reduction, but Western RCT replication is limited. Rated ★★★☆☆, meaningful human data exists but has not been independently replicated to Western clinical standards.
Approved internationally for immune-related conditions with meaningful clinical data. Longevity/anti-aging applications are more limited but emerging. An unusual case of a peptide with real international approval but US research-only status.
A GHRH analog that was previously FDA-approved. Has historical clinical use and some body composition evidence, but longevity-specific applications are preliminary. Currently available through compounding pharmacies.
Every compound in this category, fully profiled with mechanisms, evidence ratings, FDA status, and research citations.
Get the Anti-Aging & Longevity Guide, $19.99 →One-time purchase. Instant download. No subscription.